Peptide Research Library

DSIP

Main evidence: Community reports. Updated 2026-10-30.

What research and users report, not a recommendation or medical advice. Many of these products are not approved for human use. Ask your doctor. Packs report what sources say, each with its evidence label. A claim labelled community, educator, manufacturer or animal has not been validated in humans.

Summary

This information-only pack labels the available DSIP material as community-reported and separates it from verified Australian regulatory context.

What the sources say

• What it is — Research Dosing identifies DSIP as Delta Sleep-Inducing Peptide, a naturally occurring peptide associated with regulation of sleep-wake cycles. This is community-reported material and has not been validated in humans. (Community reports; Research Dosing — DSIP, 2026-05-16)
• Approval or study status — The Research Dosing page describes DSIP as currently being studied for alcohol and opioid withdrawal. This is community-reported material and has not been validated in humans. (Community reports; Research Dosing — DSIP, 2026-05-16)
• Research Dosing says that DSIP's exact mechanism is not entirely understood and describes possible interaction with the central nervous system as theory. This is community-reported material and has not been validated in humans. (Community reports; Research Dosing — DSIP, 2026-05-16)
• Research Dosing lists headache, low blood pressure, dizziness, ringing ears, sweating, and vomiting as possible effects. It also reports a potential for excessive drowsiness or neurological effects when DSIP is combined with central nervous system depressants. This is community-reported material and has not been validated in humans. (Community reports; Research Dosing — DSIP, 2026-05-16)
• The TGA states that peptide products are regulated as therapeutic goods in Australia and defines unapproved peptide products as goods not included in the ARTG. The official source does not make a DSIP-specific conclusion, so this pack does not state DSIP's product-specific Australian legal status. (Community reports; TGA — Unapproved peptide products responsibilities, 2026-04-13)

Sources

1. Research Dosing — DSIP (2026-05-16)
2. TGA — Unapproved peptide products responsibilities (2026-04-13)

Dosing, stacking and protocol details are not published here.